Effects of Vitamin D$_3$ on Inflammatory Bowel Disease in Rats via the Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88/Nuclear Factor Kappa Light Chain Enhancer of Activated B Cells Signaling Pathway

WEIWEI LIU, XUEPING LIU, YANAN XU, ZHONGSONG ZHAO AND JIANHUA LI*
Department of Gastroenterology, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Jinan 250000, Shandong Province, China

Liu et al.: Effects of Vitamin D$_3$ on Inflammatory Bowel Disease

To assess the ameliorating effects of vitamin D$_3$ on inflammatory bowel disease in rats via the Toll-like receptor 4/myeloid differential factor 88/nuclear factor kappa B signaling pathway. Thirty two rats were randomly assigned into Control group, model group (Vehicle group), low-concentration vitamin D$_3$ group (vitamin D$_3$ low group) and high-concentration vitamin D$_3$ group (vitamin D$_3$ high group). The model of inflammatory bowel disease was constructed using 3 % dextran sodium sulfate and given different concentrations of vitamin D$_3$. Disease activity index score was calculated, colon tissues were pathologically scored by hematoxylin-eosin staining, and the mRNA expression levels of Toll-like receptor 4/myeloid differential factor 88/nuclear factor kappa B were measured by quantitative reverse transcription-polymerase chain reaction. The expression levels of serum tumor necrosis factor-α, pro-inflammatory factors interleukin 1β and interleukin 6, as well as anti-inflammatory factor interleukin 10 were detected through enzyme-linked immunosorbent assay. The disease activity index score, mRNA expression levels of Toll-like receptor 4/myeloid differential factor 88/nuclear factor kappa B and expression levels of tumor necrosis factor-α, interleukin 1β and interleukin 6 were significantly higher in Vehicle group than those in Control group, while the expression level of interleukin-10 was lower in Vehicle group (p<0.05). After intervention with vitamin D$_3$, vitamin D$_3$ low group and vitamin D$_3$ high group had significantly decreased disease activity index score, messenger RNA expression levels of Toll-like receptor 4/myeloid differential factor 88/nuclear factor kappa B and expression levels of tumor necrosis factor-α, interleukin 1β and interleukin 6, increased interleukin-10 expression level, and relieved damage of colon tissues compared with Vehicle group (p<0.05). Vitamin D$_3$ ameliorates intestinal injury and colonic inflammation in inflammatory bowel disease rats by suppressing the Toll-like receptor 4/myeloid differential factor 88/nuclear factor kappa B signaling pathway and decreasing the expression of downstream pro-inflammatory factors.

Key words: Toll-like receptor 4, myeloid differential factor 88, nuclear factor kappa B, vitamin D$_3$, inflammatory bowel disease

Inflammatory bowel disease (IBD), a group of chronic and non-specific intestinal diseases including ulcerative colitis (UC) and Crohn’s disease (CD) is able to affect the entire digestive tract. It exhibits a yearly increasing incidence rate recently, but its pathogenesis remains unclear. IBD may have an association with environmental factors, genetic factors and immune disorders and the intestinal immune response is a vital player in the development, progression and treatment of IBD[1]. The nature of pathology of IBD is the injury of intestinal mucosa and repair of epithelial cells caused by massive inflammatory cells and factors in the intestine[2]. Toll-like receptors (TLRs) refer to cell transmembrane receptors and pathogen pattern recognition receptors.

*Address for correspondence
E-mail: ljhua889@163.com

Accepted 23 June 2021
Revised 01 March 2021
Received 22 August 2020
Indian J Pharm Sci 2021;83(3):569-574
in the innate immune system, which mainly mediate the interaction between microorganisms and cells and participate in inflammatory signal transduction. TLR4, a specific receptor for lipopolysaccharides (LPS), is capable of activating genes related to adaptive immunity[3]. As a downstream signal molecule of the TLR signaling pathway, myeloid differential factor 88 (MyD88) contains the TLR domain and functions as an adapter protein[4]. In the MyD88-dependent TLR4 signaling pathway, the pro-inflammatory factors [tumor necrosis factor-α (TNF-α) and interleukin 1β (IL-1β)] are released due to the activation of nuclear factor kappa B (NF-κB), and the inflammatory factors released further activate NF-κB, so the inflammation constantly amplifies and deepens and eventually develops into a cancer[5]. In many existing studies, the therapeutic effects of drugs on IBD are observed through the TLR4/MyD88/NF-κB signaling pathway. Shon et al.[6] found that Ido-1 down-regulated the TLR/MyD88/NF-κB signaling pathway to alleviate dextran sodium sulfate (DSS)-induced colitis in mice. Vitamin D (VD₃), a fat-soluble vitamin, is easily converted into VD₃ under ultraviolet light, of which the active form is 1,25(OH)₂D₃. VD₃ is involved in the calcium-phosphorus metabolism in the body and also binds to nuclear receptor VD receptor (VDR) to regulate the immune function[7]. Numerous studies have proved that VD₃ affects the pathogenesis of IBD. Erben et al.[8] found that the 1,25(OH)₂D₃ level was lower in the mouse model of IBD and patients with IBD. Arihiro et al.[9] discovered that knocking out the VDR gene in mice induced IBD that was significantly mitigated after supplementing 1,25(OH)₂D₃. However, whether VD₃ can alleviate IBD by regulating the TLR4/MyD88/NF-κB signaling pathway is rarely reported. In this study, therefore, a rat model of IBD was established to probe into the ameliorating effect of VD₃ on IBD in rats through the TLR/MyD88/NF-κB signaling pathway, hoping to provide experimental evidence for clinical treatment of IBD with VD₃.

**MATERIALS AND METHODS**

**Laboratory animals:**

A total of 32 Specific-Pathogen Free-grade male Sprague Dawley rats aged 10-12 w and weighing (200±20) g were purchased from Nankai University [production license number: SYXK (Tianjin) 2019-0003], fed with normal feed at 25°C (room temperature) and 60 % (standard humidity) on a 12 h light-12 h dark schedule (lighting) with water available ad libitum in separate cages for 1 w and then used in experiments.

**Main reagents and instruments:**

The main reagents used in this study included VD₃ (Shanghai Roche Pharmaceuticals Co., Ltd., China), DSS (Sigma, USA), TLR4, MyD88 and NF-κB antibodies (Abcam, UK), secondary antibodies (Beijing Beseec Science and Technology Co., Ltd., China), hematoxylin-eosin (HE) staining solution and RIPA lysis buffer (Shanghai Beyotime Biotechnology Co., Ltd., China), BCA protein concentration determination kit and DAB color development kit (Beijing Zhongshan Goldenbridge Biotechnology Co., Ltd., China), and hematoxylin and eosin (Beijing Solarbio Science & Technology Co., Ltd., China).

The following instruments were adopted in this study: A embedding machine (Leica, Germany), a fluorescence quantitative polymerase chain reaction (PCR) instrument (Roche, Switzerland), an E800 microscope (Nikon, Japan), a table-top freezing centrifuge (Beckman, USA), a protein electrophoresis apparatus and a transfer instrument (Bio-Rad, USA), a microplate reader (BioTek, USA), and an ultrasonic cell disruptor (Sonics, USA).

**Modeling and grouping:**

The 32 rats enrolled were randomly divided into Control group, model group (Vehicle group), low-concentration VD₃ group (VD₃ low group), and high-concentration VD₃ group (VD₃ high group). (The dosage of administration of VD₃ is 50000 IU/w based on the deficiency in adults, which is converted into a dose of 1250 IU/w in rats, and the VD₃ concentration was 180 IU/d in VD₃ low group and 540 IU/d in VD₃ high group).

The rat model of IBD was established using modified classic method of Cooper et al.[10]. The rats in Control group had free access to distilled water for 7 d and were given a gavage of distilled water at 10 o’clock every day, while those in Vehicle group drank 3 % DSS freely for 7 d and were given a gavage of distilled water every day at 10 o’clock. In VD₃ low group and VD₃ high group, rats were provided with 3 % DSS freely for 7 d and intragastrically given low-concentration VD₃ and high-concentration VD₃ separately at 10 o’clock every day.

The weight, stool, diet, drinking and movement of rats were observed and recorded every day. All rats were killed under anesthesia at 7 d after modeling, and their colon specimens were collected and stored in liquid
nitrogen.

**Disease activity index (DAI) score:**

The weight, stool viscosity, bloody stool and other conditions of rats were observed and recorded every day, based on which the DAI score was calculated (Table 1). DAI=weight loss score+stool viscosity score+bloody stool score\[^{[10]}\].

**HE staining and pathological scoring of colon tissues:**

Frozen colon tissues were taken and prepared into paraffin sections after fixation and paraffin embedding. Then, the sections were deparaffinized with xylene, dehydrated with graded ethanol and stained with hematoxylin and eosin. Thereafter, the sections were gradiently dehydrated with ethanol, permeabilized with xylene and mounted with neutral balsam, followed by observation using a microscope (200×).

The colon tissues were pathologically scored\[^{[10]}\]. Specifically, 5 fields of view were randomly selected for each section and scored according to the pathology scoring standards (Table 2).

**Measurement of mRNA expression levels of TLR4, MyD88 and NF-κB through quantitative reverse transcription-polymerase chain reaction (qRT-PCR):**

Total RNAs were extracted from frozen colon tissues using TRIzol method and reversely transcribed into cDNAs with a reverse transcription kit. Next, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal reference, the amplification was performed using the SYBR Green method under the following conditions: 95° for 5 min, 95° for 20 s and 60° for 30 s for a total of 40 cycles. After that, the relative expression levels of TLR4, MyD88 and NF-κB were calculated using the $2^{-\Delta\Delta CT}$ formula.

The PCR primer sequences were as follows:

- **TLR4:** upstream: 5'-CAGAATGAGGACTGGGTG-3' and downstream: 5'-GTGAAGGCAGAGGTGAAAG-3',
- **MyD88:** upstream: 5'-CTCGCAGTTTTGATGGTG-3' and downstream: 5'-TACCTAAGTATTTCTGGCAGT-3',
- **NF-κB:** upstream: 5'-ACTGCCGGGATGGCTACTAT-3' and downstream: 5'-TCTGGATTCGCTGGCTAATGG-3', and
- **GAPDH:** upstream: 5'-TGTTTCCTCGTCCCGTAG-3' and downstream: 5'-CAATCTCCACTTGCACACT-3'

**Detection of expression levels of pro-inflammatory factors TNF-α, IL-1β and IL-6 and the anti-inflammatory factor IL-10 in the serum by enzyme-linked immunosorbent assay (ELISA):**

The blood was drawn from the abdominal aorta of rats and centrifuged at 4° and 3500 r/min for 5 min and then diluted as per the instructions of the ELISA kit and a standard curve was plotted. Next, the content of serum TNF-α, IL-1β, IL-6 and IL-10 in rats was detected.

**Statistical analysis:**

SPSS 16.0 software was employed for statistical analysis, and GraphPad 5.01 software was adopted for plotting. The measurement data were expressed as $(\bar{x} \pm s)$ and compared between groups using independent $t$ test and among groups through single-factor analysis of variance. $p<0.05$ indicated that a difference was statistically significant.

**RESULTS AND DISCUSSION**

The rats in Control group had glossy hair, constant weight gain and normal urination and defecation,

| Score | Weight loss (%) | Stool viscosity | Bloody stool |
|-------|----------------|----------------|--------------|
| 0     | Unchanged      | Normal         | Normal       |
| 1     | 1-5            | Loose          | Occult blood positive |
| 2     | 6-10           | Loose          | Gross bloody stool |
| 3     | 11-15          | Loose stool    | Gross bloody stool |
| 4     | >15            | Loose stool    | Gross bloody stool |

| Score | Inflammation | Depth | Crypt injury | Lesion size (%) |
|-------|--------------|-------|--------------|-----------------|
| 0     | No           | No    | No           | 0               |
| 1     | Mild         | Mucosa| Destruction of 1/3 basal crypts | 1-25 |
| 2     | Severe       | Submucosa | Destruction of 2/3 basal crypts | 26-50 |
| 3     | Substrate    | Intact superficial epithelium only | 51-75 |
| 4     | Serosa       | Destruction of crypts and epithelia | 76-100 |
as well as normal drinking, eating and movement. In Vehicle group, the rats had unsmooth and shaggy hair, weight loss, loose stools, decreased drinking, eating and movement from the 3rd d, bloody stools on the 4th d, and gross bloody stools on the 6th d, and the above conditions reached the peak on the 7th d. After intervention with VD₃, the above conditions were improved in VD₃ low group and VD₃ high group compared with those in Vehicle group, with the most obvious improvement in rats in VD₃ high group. On the 7th d, the weight of rats was (230.21±3.21) in Control group, showing an upward trend, and (171.18±3.83) in Vehicle group, (179.24±2.62) in VD₃ low group and (191.65±2.17) in VD₃ high group, displaying a downward tendency (p<0.05) (fig. 1).

In Vehicle group, the DAI score of rats rose from the 3rd d and reached the peak on the 7th d. After intervention with VD₃, the DAI score declined in VD₃ low group and VD₃ high group compared with that in Vehicle group, with the most obvious decrease in VD₃ high group. The score on the 7th d was (0.13±0.35), (9.13±0.54), (5.04±0.48) and (3.71±0.32) in Control group, Vehicle group, VD₃ low group and VD₃ high group, respectively. The score was significantly higher in Vehicle group, VD₃ low group and VD₃ high group than that in Control group, while it was significantly lower in VD₃ low group and VD₃ high group than that in Vehicle group (p<0.05) (fig. 2).

The pathological score of colon tissues was (0.62±0.53) in Control group, (10.21±1.02) in Vehicle group, (6.33±1.52) in VD₃ low group, and (4.12±1.10) in VD₃ high group. Compared with that in Control group, the score was significantly increased in Vehicle group, VD₃ low group and VD₃ high group. Compared with Vehicle group, VD₃ low group and VD₃ high group had significantly reduced scores, and the score decreased markedly with rising concentration of VD₃ (P<0.05) (fig. 3).

![Fig. 1: Body weight changes. *p<0.05 vs. Control group, #p<0.05 vs. Vehicle group DAI scores](image1)

![Fig. 2: DAI scores. *p<0.05 vs. Control group, #p<0.05 vs. Vehicle group](image2)

The qRT-PCR results exhibited that the mRNA expression levels of TLR4, MyD88 and NF-κB were significantly higher in Vehicle group, VD₃ low group and VD₃ high group than those in Control group, while they were significantly lower in VD₃ low group and VD₃ high group than those in Vehicle group. With increasing concentration of VD₃, the mRNA expression levels decreased more significantly (p<0.05) (fig. 4).

Compared with Control group, Vehicle group, VD₃ low group and VD₃ high group had significantly increased serum expression levels of TNF-α, IL-1β, and IL-6, and a significantly reduced IL-10 expression level. In comparison with Vehicle group, VD₃ low group and VD₃ high group displayed significantly lowered expression levels of TNF-α, IL-1β and IL-6 and a significantly elevated IL-10 expression level. With rising VD₃ concentration, the decrease in the expression level of pro-inflammatory factors and the increase in the expression level of anti-inflammatory factors were more obvious (p<0.05).

IBD is most often diagnosed in adolescents who have higher risks of extra-intestinal complications and malnutrition than adults[11]. Patients with IBD have varying degrees of VD deficiency, and the content of VD is negatively correlated with disease activity[12]. The rat model of DSS-induced colitis shows similar clinical manifestations and pathological and immunological changes to human IBD, i.e. both rat model of DSS-induced colitis and human IBD will have symptoms such as weight loss, loss of appetite, infiltration of inflammatory cells, diarrhea and hematochezia. Therefore, in this study, rats with DSS-induced colitis were selected as the research model.

In this study, the rats freely drank 3 % DSS solution for 7 d, and the pathological score in Vehicle group was increased. There was a significant difference in above index between Control group and Vehicle group,
suggesting the successful establishment of the rat model of IBD, which is consistent with the results of previous studies\cite{13,14}. Besides, IBD manifestations were also observed in $\text{VD}_3$ low group and $\text{VD}_3$ high group, but the severity was lower than that in Vehicle group, and a higher $\text{VD}_3$ concentration indicated lower severity of IBD. These results indicate that $\text{VD}_3$ can relieve the colonic inflammation in rats with DSS-induced colitis.

In IBD patients, endotoxins will be produced due to intestinal flora disorders and infections. LPS will activate the TLR signaling pathway, and TLRs will conduct signal transduction through the MyD88-dependent pathways after recognizing LPS. The activated MyD88 is capable of activating TNF receptor associated factor 6 (TRAF6) that binds to NF-κB inhibitor kinase inhibitor (IKK) to activate NF-κB. Activated NF-κB enters the nucleus from cells and activates the expression of related inflammatory genes\cite{15,16}. For this reason, the TLR4/MyD88/NF-κB signaling pathway is deemed as one of the pathogeneses of IBD. In this study, the results of qRT-PCR uncovered that the mRNA expression levels of TLR4, MyD88 and NF-κB were significantly higher in Vehicle group than those in Control group, whereas they declined after intervention with $\text{VD}_3$, being in line with the results of previous research. It suggests that $\text{VD}_3$ can alleviate the inflammatory response in rats.
through the TLR4/MyD88/NF-κB signaling pathway. 1,25-(OH)₂D₃ can act on Th1 and Th17 cells to inhibit their secretion of pro-inflammatory factors such as IL-6, IL-1β, TNF-α and IFN-γ and up-regulate the anti-inflammatory factors like IL-4 and IL-10, thus suppressing the inflammatory response in the body [17]. NF-κB is also dominant in the modulation of inflammatory response signaling pathways, and induces the transcription and translation of inflammatory factors to release them into the blood [18]. The results of this study revealed that expression levels of serum IL-6, IL-1β and TNF-α were significantly higher in Vehicle group than those in Control group, while the IL-10 expression level was significantly lower in Vehicle group than that in Control group. After intervention with VD₃, the expression levels of IL-6, IL-1β and TNF-α declined, whereas the expression level of IL-10 rose compared with those in Vehicle group. This implies that VD₃ is able to attenuate the inflammatory response in rats by regulating the expression of inflammatory factors.

In conclusion, VD₃ impedes the TLR4/MyD88/NF-κB signaling pathway and reduces the expression of downstream inflammatory factors to mitigate intestinal injury and colonic inflammation in IBD rats. However, in-depth studies should be carried out on the mechanism by which VD relieves IBD, because IBD has a complex pathogenesis and involves many inflammatory response pathways.

Author’s contribution:

Weiwei Liu and Xueping Liu equally contributed to this work.

REFERENCES

1. de Souza HS. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opinion Gastroenterol 2017;33(4):222-9.
2. Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Translational Res 2016;8(6):2490-7.
3. Su Q, Li L, Sun Y, Yang H, Ye Z, Zhao J. Effects of the TLR4/Myd88/NF-κB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury. Cell Physiol Biochem 2018;47(4):1497-508.
4. Makkar S, Riehl TE, Chen B, Yan Y, Alvarado DM, Ciorda MA, Stenson WF. Hyaluronic acid binding to TLR4 promotes proliferation and blocks apoptosis in colon cancer. Molecular Cancer Ther 2019;18(12):2446-56.
5. Lee J, Park JR, Lee H, Jang S, Ryu SM, Kim H, et al. 1-carnosine induces apoptosis/cell cycle arrest via suppression of NF-κB/STAT1 pathway in HCT116 colorectal cancer cells. In Vitro Cell Dev Biol Anim. 2018;54(7):505-12.
6. Shon WJ, Lee YK, Shin JH, Choi EY, Shin DM. Severity of DSS-induced colitis is reduced in Idol-deficient mice with down-regulation of TLR-MyD88-NF-κB transcriptional networks. Sci Rep 2015;5(1):1-2.
7. Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J Gastroenterol 2016;22(3):933-36.
8. Erben U, Loddenkemper C, Speckermann S, Heimesaat MM, Siegmund B, Kuehl AA. Histomorphology of intestinal inflammation in inflammatory bowel diseases (IBD) mouse models and its relevance for IBD in men. Int J Clin Exp Med 2016;9:408-42.
9. Arhiro S, Nakashima A, Matsuoka M, Suto S, Uchiyama K, Kato T, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2019;25(6):1088-95.
10. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69(2):238-49.
11. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr 2015;169(11):1053-60.
12. Fletcher J, Cooper SC, Ghosh S, Hewison M. The role of vitamin D in inflammatory bowel disease: mechanism to management. Nutrients 2019;11(5):1019.
13. Hart ML, Ericsson AC, Franklin CL. Differing Complex Microbiota Alter Disease Severity of the IL-10−/− Mouse Model of Inflammatory Bowel Disease. Front Microbiol 2017;8:792.
14. Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascalfroni ID, et al. Interleukin 1β mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterol 2016;151(6):1100-4.
15. Zhou M, Xu W, Wang J, Yan J, Shi Y, Zhang C, et al. Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-κB pathway quenches intestinal inflammation and oxidative stress injury. EBioMed 2018;35:345-60.
16. Qiao CX, Xu S, Wang DD, Gao SY, Zhao SF, Zhang ML, et al. MicroRNA-19b alleviates lipopolysaccharide-induced inflammatory injury in human intestinal cells by up-regulation of Runx3. Eur Rev Med Pharmacol Sci 2018;22(16):5284-94.
17. Verlinden L, Leysens C, Beullens I, Marcelis S, Mathieu C, De Clercq P, et al. The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease. J Steroid Biochem Mol Biol 2013;136:107-11.
18. Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia-Flores Y, et al. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Communication 2017;8(1):1-3.